Zentalis Pharmaceuticals Q3 2026 Results: Net Loss of $28.8M, Loss Widens
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, azenosertib (ZN-c3), for various oncology indications including ovarian cancer. As of November 4, 2026, the company had 98,265,863 shares of common stock outstanding and is prioritizing its Phase 3 ASPENOVA and Phase 2 DENALI trials.
- Key figure
- Net loss $28.8M